NCT02574728 2026-03-02
AflacST1502
Emory University
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT03433183 2023-12-26
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01467986 2020-10-06
RIST-rNB-2011
University of Regensburg
Phase 2 Completed
NCT00634270 2017-11-17
Protocol 102
University of Alabama at Birmingham
Phase 2 Completed
NCT01490476 2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00672243 2013-08-07
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Duke University
Phase 2 Completed
NCT00016328 2013-07-18
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed